Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2025 MDS Highlights
01 July 2025 | Virtual Meeting
Updates with hypomethylating agents and combination strategies in MDS, CMML, and VEXAS syndrome
Exploring investigational agents and novel strategies for hematologic improvement in lower-risk MDS
Optimizing transplantation for myeloid neoplasms
Leveraging AI and integrative approaches to refine MDS diagnosis and treatment
Session 1: Updates with hypomethylating agents and combination strategies in MDS, CMML, and VEXAS syndrome
Efficacy of macrophage checkpoint CLEVER-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the Ph1/2 BEXMAB study
Mika Kontro University of Helsinki, Helsinki, Finland
A randomized, multicenter Phase II trial of 3-day decitabine, 3-day azacitidine, or 5-day azacitidine in lower-risk myelodysplastic syndrome
Ian Bouligny The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Durable responses to lenzilumab-azacitidine combination therapy in high-risk proliferative CMML with suppression of CBL and RAS mutant subclones
Daniel Thomas The University of Adelaide, Adelaide, Australia
Efficacy and safety of azacitidine in VEXAS syndrome: large scale study from the FRENVEX
Thibault Comont Toulouse Cancer Research Center, Toulouse, France
Panel discussion
Session 2: Exploring investigational agents and novel strategies for hematologic improvement in lower-risk MDS
Phase ll randomized trial, repurposing danazol and VBAP in low-risk myelodysplastic syndrome: REPAIR-MDS
Manoj Raghavan University of Birmingham, Birmingham, United Kingdom
Hematologic improvement and fatigue reduction with elritercept in participants with lower-risk (LR) myelodysplastic neoplasms (MDS) with non-transfusion dependent anemia: results from an ongoing Phase ll trial
Mikkael Sekeres Sylvester Comprehensive Cancer Center, Miami, FL, United States
Outcomes with imetelstat by serum erythropoietin levels in patients with lower-risk myelodysplastic syndromes who were treatment naive or who had prior treatment with erythropoiesis-stimulating agents
Rami Komrokji Moffitt Cancer Center, Tampa, FL, United States
Overall survival and duration of transfusion independence for first-line ESA-naive patients with lower-risk myelodysplastic syndromes treated with luspatercept vs epoetin alfa in the COMMANDS trial
Valeria Santini University of Florence, Florence, Italy
Preliminary efficacy and safety analysis of the MAXILUS study of luspatercept (LUSPA) initiated at the maximum approved dose in transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS)
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Panel discussion
Session 3: Optimizing transplantation for myeloid neoplasms
The randomized controlled hamlet trial shows no survival difference between haploidentical related and single HLA-loci mismatched unrelated donor transplantation in patients with high-risk AML/ALL/MDS
Johannes Schetelig University Hospital TU Dresden, Dresden, Germany
A decision support system for personalized optimization of hematopoietic stem cell transplantation timing in chronic myelomonocytic leukemia
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Panel discussion
Session 4: Leveraging AI and integrative approaches to refine MDS diagnosis and treatment
A fine-tuned foundation model for digital pathology in myelodysplastic syndromes: advancing personalized medicine
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Integrative multidimensional analysis of immune signatures using multi-omics data for patient stratification: a case study on myelodysplastic syndromes (MDS)
Nicolas Sompairac King's London College, London, United Kingdom
Artificial intelligence-enhanced analysis of HMA treatment on clinical outcomes in a large cohort of MDS patients: preliminary results from an analysis from the international consortium for MDS (ICMDS) VALIDATE database
Tariq Kewan Yale School of Medicine, New Haven, CT, United States
Panel discussion
